Importer of Controlled Substances Application: PerkinElmer, Inc., 3246-3247 [2019-01848]
Download as PDF
<![CDATA[
3246
Federal Register / Vol. 84, No. 28 / Monday, February 11, 2019 / Notices
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
this investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION:
Background.—These investigations
are being instituted, pursuant to
sections 703(a) and 733(a) of the Tariff
Act of 1930 (19 U.S.C. 1671b(a) and
1673b(a)), in response to a petition filed
on February 4, 2019, by American
Institute of Steel Construction, LLC,
Chicago, IL.
For further information concerning
the conduct of these investigations and
rules of general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A and B (19 CFR part 207).
Participation in the investigations and
public service list.—Persons (other than
petitioners) wishing to participate in the
investigations as parties must file an
entry of appearance with the Secretary
to the Commission, as provided in
sections 201.11 and 207.10 of the
Commission’s rules, not later than seven
days after publication of this notice in
the Federal Register. Industrial users
and (if the merchandise under
investigation is sold at the retail level)
representative consumer organizations
have the right to appear as parties in
Commission antidumping duty and
countervailing duty investigations. The
Secretary will prepare a public service
list containing the names and addresses
of all persons, or their representatives,
who are parties to these investigations
upon the expiration of the period for
filing entries of appearance.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
section 207.7(a) of the Commission’s
rules, the Secretary will make BPI
gathered in these investigations
available to authorized applicants
representing interested parties (as
defined in 19 U.S.C. 1677(9)) who are
parties to the investigations under the
APO issued in the investigations,
provided that the application is made
not later than seven days after the
publication of this notice in the Federal
Register. A separate service list will be
maintained by the Secretary for those
VerDate Sep<11>2014
18:05 Feb 08, 2019
Jkt 247001
parties authorized to receive BPI under
the APO.
Conference.—The Commission’s
Director of Investigations has scheduled
a conference in connection with these
investigations for 9:30 a.m. on Monday,
February 25, 2019, at the U.S.
International Trade Commission
Building, 500 E Street SW, Washington,
DC. Requests to appear at the conference
should be emailed to
preliminaryconferences@usitc.gov (DO
NOT FILE ON EDIS) on or before
February 21, 2019. Parties in support of
the imposition of countervailing and
antidumping duties in these
investigations and parties in opposition
to the imposition of such duties will
each be collectively allocated one hour
within which to make an oral
presentation at the conference. A
nonparty who has testimony that may
aid the Commission’s deliberations may
request permission to present a short
statement at the conference.
Written submissions.—As provided in
sections 201.8 and 207.15 of the
Commission’s rules, any person may
submit to the Commission on or before
February 28, 2019, a written brief
containing information and arguments
pertinent to the subject matter of the
investigations. Parties may file written
testimony in connection with their
presentation at the conference. All
written submissions must conform with
the provisions of section 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s Handbook on
E-Filing, available on the Commission’s
website at https://edis.usitc.gov,
elaborates upon the Commission’s rules
with respect to electronic filing.
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the investigations
must be served on all other parties to
the investigations (as identified by
either the public or BPI service list), and
a certificate of service must be timely
filed. The Secretary will not accept a
document for filing without a certificate
of service.
Certification.—Pursuant to section
207.3 of the Commission’s rules, any
person submitting information to the
Commission in connection with these
investigations must certify that the
information is accurate and complete to
the best of the submitter’s knowledge. In
making the certification, the submitter
will acknowledge that any information
that it submits to the Commission
during these investigations may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
and contract personnel (a) for
developing or maintaining the records
of these or related investigations or
reviews, or (b) in internal investigations,
audits, reviews, and evaluations relating
to the programs, personnel, and
operations of the Commission including
under 5 U.S.C. Appendix 3; or (ii) by
U.S. government employees and
contract personnel, solely for
cybersecurity purposes. All contract
personnel will sign appropriate
nondisclosure agreements.
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.12 of the
Commission’s rules.
By order of the Commission.
Issued: February 5, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–01730 Filed 2–8–19; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: PerkinElmer, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 13, 2019. Such persons
may also file a written request for a
hearing on the application on or before
March 13, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
DATES:
E:\FR\FM\11FEN1.SGM
11FEN1
Federal Register / Vol. 84, No. 28 / Monday, February 11, 2019 / Notices
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
December 4, 2018, PerkinElmer, Inc.,
120 East Dedham Street, Boston,
Massachusetts 02118–2852 applied to
be registered as an importer of the
following basic classes of controlled
substances:
Controlled
substance
Drug
code
Lysergic acid
diethylamide.
Thebaine ...................
Schedule
7315
I
9333
II
The company plans to import the
listed controlled substances in bulk for
manufacturing wherein the controlled
substances will be labeled with a
radioactive tracer compound and sold
for research purposes to its customers.
Thebaine (9333) will be used to
manufacture the derivative
Diprenorphine.
Dated: February 4, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–01848 Filed 2–8–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Robert T. Perez, M.D.; Decision and
Order
On September 28, 2018, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause to Robert T. Perez, M.D.
(Registrant), of Santa Ana, California.
The Show Cause Order proposed the
revocation of Registrant’s DEA
Certificate of Registration No.
BP4317740 on the ground that he does
‘‘not have authority to handle controlled
substances in the State of California, the
[S]tate in which [he] is registered with
the DEA.’’ Appendix (App.) 1 (Order to
Show Cause) to Government’s Request
VerDate Sep<11>2014
18:05 Feb 08, 2019
Jkt 247001
for Final Agency Action (RFAA), at 1
(citing 21 U.S.C. 823(f), 824(a)(3)).
With respect to the Agency’s
jurisdiction, the Show Cause Order
alleged that Registrant is the holder of
Certificate of Registration No.
BP4317740, pursuant to which he is
authorized to dispense controlled
substances as a practitioner in schedules
II through V, at the registered address of
1420 E. Edinger Ave., Suite 123, Santa
Ana, California. Id. The Order also
alleged that this registration does not
expire until March 31, 2019. Id.
Regarding the substantive grounds for
the proceeding, the Show Cause Order
alleged that on or about August 27,
2018, the Medical Board of California
(MBC) issued ‘‘an Order On Noticed
Petition For Order of Interim
Suspension’’ (hereinafter ‘‘Interim
Order’’) that ‘‘suspended’’ Registrant’s
‘‘authority to prescribe and administer
controlled substances in the State of
California, the [S]tate in which [he] is
registered with the DEA.’’ Id. at 2. The
Show Cause Order more specifically
alleged that the Interim Order stated
that Registrant ‘‘shall not ‘[p]ossess,
order, purchase, receive, prescribe,
furnish, administer, or otherwise
distribute controlled substances or
dangerous drugs as defined by federal or
state law.’’ Id. As a result, the Show
Cause Order alleged that ‘‘DEA must
revoke [his] registration . . . based upon
[his] lack of authority to handle
controlled substances in the State of
California.’’ Id. (citing 21 U.S.C.
824(a)(3)). Id.
The Show Cause Order notified
Registrant of (1) his right to request a
hearing on the allegations or to submit
a written statement in lieu of a hearing,
(2) the procedure for electing either
option, and (3) the consequence for
failing to elect either option. Id. at 2–3.
(citing 21 CFR 1301.43). The Order also
notified Registrant of his right to submit
a corrective action plan. Id. at 3–4
(citing 21 U.S.C. 824(c)(2)(C)).
With respect to service, a Diversion
Investigator (DI) with DEA’s Los
Angeles Field Division executed a
Declaration on January 8, 2019 stating
that she ‘‘learned that [Registrant] was
incarcerated at Santa Ana Jail located in
Santa Ana, CA.’’ App. 10 (Declaration of
DI) to RFAA, at 1. As a result, the DI
stated that on October 16, 2018, she
‘‘personally served a copy of the [Show
Cause Order] on [Registrant] at the
prison.’’ Id. The Declaration also
attached DEA Form 12 Receipt for Cash
or Other Items bearing ‘‘Registrant’s
signature confirming his receipt’’ of the
Show Cause Order on October 16, 2018.
Id. at 2; Attachment A to App. 10, at 1.
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
3247
On January 17, 2019, the Government
forwarded its Request for Final Agency
Action and evidentiary record to my
Office. In its Request, the Government
represents that more than 30 days have
passed since Registrant had been served
and that ‘‘DEA has not received a
request for hearing or any other reply
from him.’’ RFAA, at 5. Based on the
Government’s representation and the
record, I find that more than 30 days
have passed since the Order to Show
Cause was served on the Registrant, and
he has neither requested a hearing nor
submitted a written statement in lieu of
a hearing. See 21 CFR 1301.43(d).
Accordingly, I find that Registrant has
waived his right to a hearing or to
submit a written statement and issue
this Decision and Order based on
relevant evidence submitted by the
Government. See id. I make the
following findings.
Findings of Fact
Registrant is the holder of DEA
Certificate of Registration No.
BP4317740, pursuant to which he is
authorized to dispense controlled
substances in schedules II through V as
a practitioner at the registered address
of 1420 E. Edinger Ave., Suite 123,
Santa Ana, California. App. 2
(Certification of Registration Status) to
Govt. Mot., at 1. This registration does
not expire until March 31, 2019. Id.
Registrant is also the holder of
California Physician’s and Surgeon’s
License No. G80178, which was issued
to him in 1994 by the MBC. App. 8 to
Govt. Mot., at 2. However, on August 27,
2018, an Administrative Law Judge of
the MBC issued an Interim Order
suspending Registrant’s medical license
after determining that, under California
law, he was ‘‘mentally incompetent to
practice medicine safely’’ and that
‘‘[p]ermitting [Registrant] to continue to
engage in the unrestricted practice of
medicine will endanger the public
health, safety and welfare.’’ Id. at 7–8.1
Among other things, the Interim Order
stated that, pending a full
administrative determination, Registrant
‘‘shall not’’ ‘‘[p]ractice or attempt to
practice any aspect of medicine in the
1 The California ALJ issued the Interim Order
after considering the allegations set forth in
multiple Accusations that the MBC’s Executive
Director filed with the MBC from 2015–2018
alleging that Registrant, inter alia, (1) engaged in
dishonest acts toward a female patient; (2) failed to
maintain adequate and accurate records; (3)
engaged in unprofessional conduct; (4) engaged in
sexual misconduct and unprofessional misconduct
related to Registrant’s romantic relationship with a
female patient who subsequently became his wife;
and (5) failed to participate in professional and
ethical courses and to provide MBC-mandated
quarterly declarations. App. 8 to RFAA, at 2–7; see
also Apps. 3–7 to RFAA.
E:\FR\FM\11FEN1.SGM
11FEN1
]]>Agencies
[Federal Register Volume 84, Number 28 (Monday, February 11, 2019)]
[Notices]
[Pages 3246-3247]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01848]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: PerkinElmer, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before March 13, 2019. Such
persons may also file a written request for a hearing on the
application on or before March 13, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
[[Page 3247]]
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on
December 4, 2018, PerkinElmer, Inc., 120 East Dedham Street, Boston,
Massachusetts 02118-2852 applied to be registered as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide............ 7315 I
Thebaine.............................. 9333 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
bulk for manufacturing wherein the controlled substances will be
labeled with a radioactive tracer compound and sold for research
purposes to its customers. Thebaine (9333) will be used to manufacture
the derivative Diprenorphine.
Dated: February 4, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-01848 Filed 2-8-19; 8:45 am]
BILLING CODE 4410-09-P
